Article
The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.
Medical oncology (Northwood, London, England) - 1 Jan 2015
Akman Tulay, Oztop Ilhan, Baskin Yasemin, Akbarpour Mahdi, Unal Olcun Umit, Oflazoglu Utku, Ellidokuz Hulya, Lebe Banu
Abstract excerpt
Data regarding the prognostic importance of BRAFV600 tumor mutations in high-risk, non-metastatic, stage 2 and 3 malignant melanoma (MM) patients are controversial. There is not sufficient information in the medical literature regarding the reliability of BRAF mutations as a predictive factor in prognosis and adjuvant treatment decision issues in this patient group. The data of 50 operated high-risk,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.